NasdaqGS:BRKR

Stock Analysis Report

Executive Summary

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.


Snowflake Analysis

Outstanding track record with adequate balance sheet.


Similar Companies

Share Price & News

How has Bruker's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BRKR has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.6%

BRKR

0.4%

US Life Sciences

0.06%

US Market


1 Year Return

31.9%

BRKR

18.6%

US Life Sciences

19.4%

US Market

Return vs Industry: BRKR exceeded the US Life Sciences industry which returned 18.6% over the past year.

Return vs Market: BRKR exceeded the US Market which returned 19.4% over the past year.


Shareholder returns

BRKRIndustryMarket
7 Day-2.6%0.4%0.06%
30 Day-8.2%-1.9%1.1%
90 Day-0.5%8.7%8.9%
1 Year32.4%31.9%18.9%18.6%21.9%19.4%
3 Year107.7%104.8%93.9%92.6%48.9%39.3%
5 Year169.6%164.1%122.1%119.0%71.9%53.1%

Price Volatility Vs. Market

How volatile is Bruker's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bruker undervalued compared to its fair value and its price relative to the market?

37.15x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BRKR ($49.25) is trading above our estimate of fair value ($35.25)

Significantly Below Fair Value: BRKR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BRKR is good value based on its PE Ratio (37.1x) compared to the Life Sciences industry average (37.4x).

PE vs Market: BRKR is poor value based on its PE Ratio (37.1x) compared to the US market (18.3x).


Price to Earnings Growth Ratio

PEG Ratio: BRKR is poor value based on its PEG Ratio (2.5x)


Price to Book Ratio

PB vs Industry: BRKR is overvalued based on its PB Ratio (9x) compared to the US Life Sciences industry average (5.7x).


Next Steps

Future Growth

How is Bruker forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

15.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BRKR's forecast earnings growth (15% per year) is above the savings rate (1.7%).

Earnings vs Market: BRKR's earnings (15% per year) are forecast to grow faster than the US market (14.2% per year).

High Growth Earnings: BRKR's earnings are forecast to grow, but not significantly.

Revenue vs Market: BRKR's revenue (5.5% per year) is forecast to grow slower than the US market (7.6% per year).

High Growth Revenue: BRKR's revenue (5.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BRKR's Return on Equity is forecast to be high in 3 years time (23.6%)


Next Steps

Past Performance

How has Bruker performed over the past 5 years?

19.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BRKR has high quality earnings.

Growing Profit Margin: BRKR's current net profit margins (10.2%) are higher than last year (5.2%).


Past Earnings Growth Analysis

Earnings Trend: BRKR's earnings have grown by 19.1% per year over the past 5 years.

Accelerating Growth: BRKR's earnings growth over the past year (110.5%) exceeds its 5-year average (19.1% per year).

Earnings vs Industry: BRKR earnings growth over the past year (110.5%) exceeded the Life Sciences industry 16.6%.


Return on Equity

High ROE: BRKR's Return on Equity (23.7%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Bruker's financial position?


Financial Position Analysis

Short Term Liabilities: BRKR's short term assets ($1.4B) exceed its short term liabilities ($643.0M).

Long Term Liabilities: BRKR's short term assets ($1.4B) exceed its long term liabilities ($833.5M).


Debt to Equity History and Analysis

Debt Level: BRKR's debt to equity ratio (59.1%) is considered high.

Reducing Debt: BRKR's debt to equity ratio has increased from 43.7% to 59.1% over the past 5 years.

Debt Coverage: BRKR's debt is well covered by operating cash flow (40.5%).

Interest Coverage: BRKR's interest payments on its debt are well covered by EBIT (20.2x coverage).


Balance Sheet

Inventory Level: BRKR has a high level of physical assets or inventory.

Debt Coverage by Assets: BRKR's debt is covered by short term assets (assets are 2.8x debt).


Next Steps

Dividend

What is Bruker's current dividend yield, its reliability and sustainability?

0.32%

Current Dividend Yield


Dividend Yield vs Market

company0.3%marketbottom25%1.4%markettop25%3.7%industryaverage0.3%forecastin3Years0.3%

Current dividend yield vs market & industry

Notable Dividend: BRKR's dividend (0.32%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.43%).

High Dividend: BRKR's dividend (0.32%) is low compared to the top 25% of dividend payers in the US market (3.7%).


Stability and Growth of Payments

Stable Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: BRKR is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BRKR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.8yrs

Average management tenure


CEO

Frank Laukien (59yo)

29yrs

Tenure

US$4,479,899

Compensation

Dr. Frank H. Laukien, Ph.D., has been the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Executi ...


CEO Compensation Analysis

Compensation vs Market: Frank's total compensation ($USD4.48M) is about average for companies of similar size in the US market ($USD6.27M).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Frank Laukien
Chairman29yrsUS$4.48m25.9% $2.0b
Gerald Herman
CFO, VP & Corporate Controller1.9yrsUS$1.12m0.0014% $112.8k
Mark Munch
Executive VP and President of Bruker Nano Group & Bruker Nano Surfaces Division4.6yrsUS$1.82m0.019% $1.5m
Juergen Srega
President of Bruker CALID Group & Bruker Daltonics Division7.1yrsUS$1.39m0.043% $3.4m
Falko Busse
President of Bruker BioSpin Group1.8yrsUS$1.38m0.0015% $119.8k
Miroslava Minkova
Director of Investor Relations & Corporate Development0yrsno datano data
Richard Stein
Secretary20.1yrsUS$16.00kno data
Collin D'Silva
President of Chemical Analysis Division9.8yrsUS$1.10mno data
Stacey Desrochers
Treasurer & Director of Investor Relations11.9yrsno datano data
Urban Faeh
President of Bruker Optics Division & Managing Director of Bruker Optik GmbH10.1yrsno datano data

9.8yrs

Average Tenure

61yo

Average Age

Experienced Management: BRKR's management team is seasoned and experienced (9.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Frank Laukien
Chairman29yrsUS$4.48m25.9% $2.0b
John Ornell
Independent Director4.5yrsUS$218.03k0.0052% $406.8k
Robert Rosenthal
Independent Director4.3yrsUS$203.03k0.0052% $406.8k
Richard Packer
Independent Director12.8yrsUS$215.60k0.032% $2.5m
William Linton
Lead Director15.9yrsUS$198.03k0.047% $3.7m
Gilles Martin
Independent Director6.1yrsUS$185.03k0.0052% $406.8k
Adelene Perkins
Independent Director2.8yrsUS$200.78k0.0040% $315.0k
Hermann Requardt
Independent Director4.5yrsUS$193.03k0.0052% $406.8k
Marc Kastner
Independent Director5.1yrsUS$191.87k0.0023% $175.8k
Cynthia Friend
Independent Director3.8yrsUS$190.15k0.0052% $406.8k

4.8yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BRKR's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bruker Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bruker Corporation
  • Ticker: BRKR
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.778b
  • Shares outstanding: 153.99m
  • Website: https://www.bruker.com

Number of Employees


Location

  • Bruker Corporation
  • 40 Manning Road
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BRKRNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDAug 2000
BKDDB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2000
BRKR *BMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNAug 2000

Biography

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology, and diagnostics companies; chemical, food and beverage, clinical, and polymer companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, environmental and clinical microbiology laboratories, and hospitals and government departments and agencies, as well as agriculture, and food and beverage safety companies; nanotechnology, semiconductor, and industrial companies; and raw material manufacturers and other businesses through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 00:06
End of Day Share Price2020/02/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.